Admetsys is excited to collaborate with Hospira in putting patient safety first, actively defending against hypoglycemia in patients at diabetic risk.
Boston, MA (PRWEB) January 26, 2016
Admetsys, the biomedical technology company that has developed the world's first automated blood glucose control system for hospital and surgical care, today announced that it has entered into an agreement with Hospira for supply of private label 50% Dextrose for Injection (USP) in Hospira's Ansyr™ II polypropylene syringe system. The dextrose syringes will be used with Admetsys' artificial pancreas system to increase precision of glucose control and safeguard patients from potential hypoglycemic episodes during hospitalization.
"Admetsys is excited to collaborate with Hospira in putting patient safety first, actively defending against hypoglycemia in patients at diabetic risk," said Jeff Valk, Chief Executive Officer of Admetsys. "This marks an important step in Admetsys' mission to bring high-precision automation to hospital metabolic regulation, simultaneously improving patient outcomes while reducing the cost of care.”
Diabetes is the fastest-growing cause of inpatient and surgical care costs in the world. With over 40% of patients admitted to hospital now at diabetic risk, the decades-old manual techniques for controlling glucose levels in these patients have become unsustainable for healthcare institutions. High glucose levels prevent healing, increase risk of complications, and lengthen hospital stays, driving up care costs. Low glucose levels risk seizure, coma, and even death. With increasing pressure to reduce care costs while ensuring predictable, positive outcomes, hospitals are seeking new generations of medical technology to amplify clinician skill sets and scale their ability to provide care.
Admetsys' artificial pancreas system is specifically designed to improve the outcomes and care dynamics of hospitalized patients at diabetic risk. The system precisely controls blood glucose, while protecting against hypoglycemia, by infusing counterbalancing insulin and dextrose medications. Admetsys technology monitors blood glucose levels in real time, creates a computational model of the patient’s metabolism, and delivers finely-optimized treatment—insulin to lower high glucose levels and dextrose to raise and support falling levels.
Video – Learn more about the novel design and features of the Admetsys treatment system here: http://www.admetsys.com/.
Admetsys Corp. is an innovative biomedical technology company that has developed the world’s first automated blood glucose control system (artificial pancreas) for use in hospital and surgical care. The company is headquartered in Boston, MA. Learn more at http://www.admetsys.com.
Hospira, Inc. is the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars. Through its broad, integrated portfolio, Hospira is uniquely positioned to Advance Wellness™ by improving patient and caregiver safety while reducing healthcare costs. The company is headquartered in Lake Forest, Ill. Learn more at http://www.hospira.com.
Device not yet cleared for commercial sale. Limited in the USA to investigational use.